Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.
Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. · 2006
Read Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. by Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. (2006) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2361103.txt.
Introduction
Hiraoka and co-authors studied immune cells inside lung tumors in 2006. The cancer was non-small-cell lung carcinoma, the most common form of lung cancer. They counted two kinds of T cells, immune cells marked CD8 and CD4, in tumors removed from 109 patients.
CD8 cells alone carried no link to survival. Patients whose tumors held high levels of both cell types lived significantly longer than all other groups. A combined analysis that adjusted for other factors still marked the double-high pattern as an independent sign of better outcome. The authors argued the two cell types cooperate. CD4 cells orchestrate the immune attack, while CD8 cells kill cancer cells directly, and together they mount a stronger response than either alone.
Catalog record
| CREATOR | Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. |
|---|---|
| YEAR | 2006 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma By K Hiraoka, M Miyamoto, Y Cho, M Suzuoki, T Oshikiri, Y Nakakubo, T Itoh, T Ohbuchi, S Kondo, H Katoh Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6602934 ABSTRACT The purpose of this study was to clarify the relationship between the number of tumour-infiltrating T lymphocytes and the clinicopathological features and clinical outcome in patients with non-small-cell lung cancer (NSCLC). Tissue specimens from 109 patients who underwent surgical resection for NSCLC were immunohistochemically analysed for CD4 and CD8 expression. Patients were classified into two groups according to whether their tumours exhibited a ‘high’ or ‘low’ level of CD8+ or CD4+ lymphocyte infiltration. Although the level of infiltration by CD8+ T cells alone had no prognostic significance, the survival rate for patients with both ‘high’ CD8+ and ‘high’ CD4+ T-cell infiltration was significantly higher than that for the other groups (log-rank test, P=0.006). Multivariate analysis indicated that concomitant high CD8+ and high CD4+ T-cell infiltration was an independent favourable prognostic factor (P=0.0092). In conclusion, the presence of high levels of both CD8+ T cells and CD4+ T cells is a significant indicator of a better prognosis for patients with NSCLC, and cooperation between these cell populations may allow a significantly more potent antitumour response than either population alone. Lung cancer is one of the most common malignancies in the world, and despite remarkable advances in diagnosis and treatment for the disease, the prognosis in most cases remains poor. Non-small-cell lung cancer (NSCLC) represents about 75–80% of all lung cancers, and its overall 5-year survival rate is less than 12–15% (Ihde, 1992; Non-small Cell Lung Cancer Collaborative Group, 1995; Jemal et al, 2005). These facts make clear the need for new parameters that will allow better prognostic evaluation for this malignancy and more reliable identification of patients likely to benefit from adjuvant therapy. In a variety of human solid cancers, tumour-infiltrating T lymphocytes (TILs) are considered to play important roles in anticancer immunomechanisms of the tumour-bearing host. Among TILs, most CD8+ T cells are cytotoxic T lymphocytes that recognise particular tumour-associated antigens presented on MHC class I molecules at the cancer cell surface and possess the ability to destroy cancer cells directly. The favourable prognostic significance of the presence of tumour-infiltrating CD8+ T cells was previously reported in a variety of cancers, including colorectal cancer, oesophageal cancer, pancreatic cancer, bile duct cancer and gallbladder cancer (Naito et al, 1998; Nakano et al, 2001; Schumacher et al, 2001; Cho et al, 2003; Nakakubo et al, 2003; Oshikiri et al, 2003; Fukunaga et al, 2004). In NSCLC, however, the relationship between patient prognosis and the presence of TILs is still obscure. The infiltration of natural killer cells or macrophages into tumours was previously found to indicate a favourable prognosis (Takeo et al, 1986; Takanami et al, 2001), whereas the presence of tumour-infiltrating CD8+ T cells was not found to be a predictor of patient survival (Mori et al, 2000; Wakabayashi et al, 2003). CD4+ T cells play a central role in orchestrating the immune response to cancer. Essentially, CD4+ T cells recognise peptides presented on MHC class II molecules expressed primarily on antigen-presenting cells. Although most tumour cells do not express MHC class II molecules, CD4+ T cells can effect an antitumour response in the absence of CD8+ T cells by secreting cytokines, such as interferon-γ (Mumberg et al, 1999; Qin and Blankenstein, 2000), or by activation and recruitment of effector cells such as macrophages and eosinophils (Greenberg, 1991; Hung et al, 1998). However, the main role of CD4+ T cells in the immune response to cancer is to prime CD8+ cells and maintain their proliferation. The purpose of the present study was to evaluate the infiltration of CD4+ and CD8+ T cells by immunohistochemistry in order to clarify the individual or synergistic role of TILs in NSCLC. MATERIALS AND METHODS Patients and tissue specimens Tissue specimens from 109 patients who underwent surgical resection for NSCLC between 1994 and 1996 in the Department of Thoracic Surgery at Minami-Ichijo Hospital were studied. These cases were histopathologically composed of 58 cases of adenocarcinoma, 40 of squamous cell carcinoma, seven of large cell carcinoma, three of adeno-squamous cell carcinoma and one of carcinosarcoma. Surgical resection was not performed in patients presenting with distant site metastases. None of these patients received either preoperative radiation or chemotherapy. Our series included 71 men and 38 women with a mean age of 63 years (range 39–80). Follow-up data for each of these patients was collected for at least 5 years, and 52 patients (48%) died during the follow-up period. All specimens were fixed in 10% formalin and embedded in paraffin wax. Unstained 4-μm sections were then cut from paraffin blocks for immunohistochemical analysis. Histological classification of tumours was based on the World Health Organization criteria. All tumours were staged according to the pTNM pathological classification of the UICC (International Union Against Cancer) (Sobin and Wittekind, 1997). Immunohistochemical examination For immunohistochemical analysis, formalin-fixed and paraffin-embedded sections were deparaffinised in xylene and rehydrated through a graded series from ethanol to water. Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide for 10 min. After washing in phosphate-buffered saline (PBS, pH 7.4) twice, the sections were incubated with 10% normal goat serum for 5 min and then incubated overnight at 4°C with the primary antibodies at the following dilutions: anti-CD8 mouse monoclonal antibody (C8/144B; DAKO, Glostrup, Denmark) 1 : 50, anti-CD4 mouse monoclonal antibody (1F6; Novocastra, Newcastle, UK) 1 : 50. For negative controls, we used 10% normal mouse serum in place of primary antibody. After three additional washes, a biotinylated goat anti-mouse antibody (Histofine SAB-PO kit; Nichirei Co., Tokyo, Japan) was applied at room temperature for 30 min. After the sections were washed in PBS three times, freshly prepared 3,3′-diaminobenzidine tetrahydrochloride (Histofine Simple stain DAB Solution; Nichirei Corporation, Tokyo, Japan) was used to visualise antibody binding and the sections were washed in distilled water. Sections were counterstained with haematoxylin and mounted in Permount. Evaluation and classification of CD8+ and CD4+ T cells Tumour-infiltrating CD8+ T cells were classified into two groups by their location: CD8+ T cells within cancer stroma adjacent to cancer cell nests, or CD8+ T cells within the cancer cell nests themselves. For each group, we counted the number of CD8+ T cells with a magnification of × 200 (Olympus Optical Co., Ltd, Tokyo, Japan). The number of CD4+ T cells in cancer stroma were also counted and classified in the same way. Five areas containing the highest abundance of TILs were evaluated in each case. All counting was performed independently by three investigators of this study without knowledge of the patients' background or outcome, and immunoreactivity in each section was represented by the median scores. Statistical analysis Correlations between the numbers of both CD8+ T cells and CD4+ T cells with the patients' clinicopathological variables were analysed by the χ2 test or Fisher's exact probability test. Correlation coefficient was described as r, and r>0.7 was defined as a strong correlation. Univariate analysis of the survival data was performed using survival curves that applied the Kaplan–Meier method with